Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (231-240 of 300) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
British Journal of Haematology|June 13, 2009
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaJonathan W Friedberg, Jennifer L Kelly, Donna Neuberg, et al.
Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Journal of the National Cancer Institute. Monographs|November 16, 2017
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion ReportDan Xi, Ting Bao, Qi Chen, et al.
Eclinicalmedicine|December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialJonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS StudyLaurie H Sehn, Andre Goy, Fritz C Offner, et al.
Pageof 30

Showing results (231-240 of 300) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
British Journal of Haematology|June 13, 2009
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaJonathan W Friedberg, Jennifer L Kelly, Donna Neuberg, et al.
Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Journal of the National Cancer Institute. Monographs|November 16, 2017
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion ReportDan Xi, Ting Bao, Qi Chen, et al.
Eclinicalmedicine|December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialJonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS StudyLaurie H Sehn, Andre Goy, Fritz C Offner, et al.
Pageof 30